Tildrakizumab Efficacy by Metabolic Syndrome Status in Psoriasis: Post Hoc Analysis of 3-Year Data from the Phase 3 Resurface 1 And Resurface 2 Studies. J of Skin 2020, 4 (5), s42. https://doi.org/10.25251/skin.4.supp.42.